ArticleThe journal of headache and pain2026
Tear fluid Calcitonin gene-related peptide in patients with idiopathic intracranial hypertension headache - a prospective case-control study.
Article in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeadache is the most common symptom of idiopathic intracranial hypertension (IIH) and may persist despite therapy, with a significant impact on quality of life. Since calcitonin gene-related peptide (CGRP) plays a crucial role in the pathophysiology and management of primary headaches such as migraine, this raises the question whether CGRP also contributes to headache in IIH. Therefore, we compared tear fluid CGRP levels between IIH patients with headache and healthy controls, and in IIH patients before and after CSF pressure normalization by therapeutic lumbar puncture.
methodsIIH patients with headache attributed to IIH and healthy controls were included. To avoid confounding with chronic migraine, IIH patients with a chronic migraine phenotype were excluded. Tear fluid was collected from IIH patients and controls. In IIH patients, an additional measurement was performed approximately 3 h after therapeutic lumbar puncture. CGRP levels were analyzed using a commercially available ELISA.
resultsTwenty-three IIH patients (all female; age: 34.0 ± 8.8 years) and 20 healthy controls (all female, age: 25.7 ± 5.5 years) were included. IIH patients had 16.4 ± 12.3 headache days per month and headache was mostly bilateral and pressing. Baseline tear fluid CGRP levels were significantly lower in IIH patients compared to healthy controls (2.4 ± 1.2 ng/ml vs. 4.9 ± 4.2 ng/ml, p < 0.001). There was no significant change in CGRP levels in IIH patients before vs. after therapeutic lumbar puncture (2.4 ± 1.2 vs. 2.4 ± 1.7 ng/ml, p = 0.236). Similarly, in the subgroup with immediate headache improvement, CGRP levels remained unchanged (before: 2.2 ± 0.9 ng/ml, after: 2.8 ± 2.4 ng/ml; p = 0.674).
conclusionsTear fluid CGRP levels were lower in IIH patients with headache but without a chronic migraine phenotype compared to healthy controls. In addition, CSF pressure normalization was not associated with changes in CGRP levels after 3 h. These results do not support a major role of CGRP in IIH-associated headache without a chronic migraine phenotype.
trial registrationThe study was previously registered at the German Clinical Trial Register (DRKS www.drks.de) (DRKS00025278), Trial registration date 25.06.2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.